Siamab Therapeutics
Newton · Founded 2006
About Siamab Therapeutics
Siamab Therapeutics is a biopharmaceutical company that develops therapies targeting abnormal carbohydrates found only on cancer cells. It has developed a platform of technologies that enables the discovery and development of anti-TACA therapeutic antibodies. The company’s core technologies were licensed from the laboratory of Ajit Varki, a professional in glycobiology and sialic-acid biochemistry. It has brought together a team of scientists and advisors in oncology, glycoimmunology, and antibody engineering to support its anti-TACA antibody discovery and development programs. Siamab Therapeutics was founded in 2006 and is headquartered in Newton, M.A.
Company Facts
- Founded: 2006
- Legal name: Sialix, Inc.
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.6M
- Last round: Series Unknown (Mar 2016)
- Website: siamab.com
- Phone: (800) 513-1569
Canonical: https://fsome.com/organization/siamab-therapeutics-8370166 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.